AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder

Marignier, R; Pittock, SJ; Paul, F; Kim, HJ; Bennett, JL; Weinshenker, BG; Wingerchuk, DM; Green, AJ; Fujihara, K; Cutter, G; Aktas, O; Hartung, HP; Drappa, J; Ratchford, JN; She, DW; Smith, M; Rees, W; Cimbora, D; Katz, E; Cree, BAC

Marignier, R (通讯作者)，Hosp Civils Lyon, Serv Neurol Sclerose Plaques Pathol Myelin & Neur, Hop Neurol Pierre Wertheimer, GH Est,59 Blvd Pinel, F-69677 Bron, France.

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022; 57 ():

Abstract

Background: The N-MOmentum trial, a double-blind, randomized, placebo-controlled, phase 2/3 study of inebilizumab in neuromyelitis optica spectrum dis......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索